ADMS Adamas Pharma NASDAQ Apr 2026 Pre-Mkt $8.22: Oversold bounce 10.7% upside

ADMS stock trades at $8.22 pre-market on NASDAQ on 01 Apr 2026. Volume is heavy today at 3,151,400 shares, or 2.35x the average, creating an oversold bounce setup traders can consider. The 50-day average price sits at $7.00 and the 200-day average sits at $5.55, both below current price and supporting a short-term mean-reversion trade. We outline technical triggers, fundamental risks, and a practical trade plan for an oversold bounce.

ADMS stock snapshot and intraday data

Adamas Pharmaceuticals, Inc. (ADMS) trades on NASDAQ in the United States at $8.22 pre-market with a day low $8.18 and day high $8.25. Year range sits at $4.02 low and $9.15 high. Today’s volume is 3,151,400, vs average volume 1,338,689, giving a relative volume of 2.35. The enterprise value is $58,304,000.00 and the company operates in Healthcare, Drug Manufacturers – Specialty & Generic.

Why the oversold bounce setup matters for ADMS stock

A large volume spike above the 50-day average supports a short-term rebound trade. ADMS has risen from its 50-day average of $7.00 to $8.22, showing momentum back into the range. The stock’s recent stretch from the 52-week low of $4.02 to current price leaves room for mean reversion toward the year high of $9.15. Traders watching an oversold bounce should use volume and a clean close above $8.50 as confirmation.

Fundamental picture: ADMS financials and valuation

Adamas reports mixed fundamentals that matter to investors. Revenue per share trailing twelve months is $2.12 and cash per share is $2.37. Net income per share is negative at -$1.63 and operating cash flow per share is -$1.44, reflecting ongoing R&D and operating costs. Key valuation signals include a negative PE of -5.04 and price averages that point to recovery potential. Current ratio is 3.20, which supports liquidity but the company shows long inventory days at 1,306.33, a structural weakness for margins.

Meyka AI grades ADMS and model forecast

Meyka AI rates ADMS with a score out of 100: 66.24 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of $9.10 and a 12-month target of $15.04. Versus the current $8.22, the monthly projection implies +10.69% upside and the 12-month projection implies +82.86% upside. Forecasts are model-based projections and not guarantees.

Catalysts, risks, and clinical timeline for ADMS stock

Near-term catalysts include GOCOVRI sales momentum and clinical readouts for ADS-5102 and ADS-4101. A positive Phase III outcome or stronger product uptake would support the Meyka forecast. Main risks are continued cash burn, long days of inventory, and regulatory or clinical setbacks. We link company details for context: Adamas Pharmaceuticals and profile data at Financial Modeling Prep.

Trading plan and technical levels for the oversold bounce

A practical oversold-bounce entry is a confirmed close above $8.50 on continued volume. Short-term price target is $9.50, with a conservative 12-month target of $15.00 aligned to our forecast. Use a stop loss near $7.10 to limit downside if the bounce fails. Position size should account for volatility; ADMS shows ATR $0.07 and relative volume 2.35 today. For more on the name see the Meyka page: ADMS on Meyka.

Final Thoughts

ADMS stock at $8.22 pre-market on 01 Apr 2026 presents a clear oversold bounce setup supported by heavy volume. Technicals favor a short-term rebound if the market confirms a close above $8.50, with a practical near-term target around $9.50. Meyka AI’s forecast model projects $9.10 in the next month and $15.04 in 12 months, implying +10.69% and +82.86% upside versus current price. Fundamentals are mixed: the company has $2.37 cash per share and a current ratio of 3.20, yet profitability and inventory days remain concerns. Traders should treat this as a tactical trade, size positions for volatility, and use a stop near $7.10. Remember that Meyka AI provides an AI-powered market analysis platform and that forecasts are model-based projections and not guarantees. Monitor clinical and sales updates closely, as success or setbacks in ADS-5102 or GOCOVRI would materially change the outlook.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.